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ABSTRACT
We conducted a systematic review and meta-analysis on the effect of different exercise
interventions on fatigue in patients with breast cancer undergoing active therapy. We
found that exercise generally improves fatigue outcomes at 12 weeks after initiation of
the exercise intervention. Aerobic exercise intervention improved fatigue, but anaerobic
and combination regimens did not show improvement compared to controls. Moreover,
no exercise intensity was found to be superior compared to controls. Our findings
revealed that there is a need for standardization of exercise regimens in studies in order to
identify the most effective exercise regimen.
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Introduction
Breast cancer is one of the most common cancers in the world and in the United States.
Its treatment can have significant short and long term impacts on the patient’s Health
Related Quality of Life (HRQoL), especially fatigue. Fatigue is one of the many domains
of HRQoL, and is the most commonly reported side effects of cancer therapy. Physical
activity is increasingly incorporated into cancer treatment because of its benefits to
HRQoL outcomes such as fatigue. Below is a discussion on the epidemiology of breast
cancer, and the effects of treatment on fatigue, followed by an overview of HRQoL, its
domains, particularly fatigue, and clinical significance. The introduction will conclude
with an exploration of the types of physical activity regimens. The overall aim of this
research is to compare the effects of different exercise regimens on fatigue.
Breast Cancer Epidemiology
Breast cancer (BC) is the most common cancer in women [1], with more than 1.7 million
new worldwide cases in 2012. This is an increase of 18% from 2008, and is predicted to
reach 3.2 million by 2050 [2]. BC is also a leading cause of cancer death in women, with
522,000 worldwide deaths in 2012, second only to lung cancer [2]. The incidence of BC
is highest in high income countries, where outcomes have also improved the most [3].
However, the majority of BC deaths occur in low and middle income countries, where the
incidence has been increasing by about 5% per year [4, 5].
In the United States, one in eight women will develop BC in their lifetime [6]. The
American Cancer Society reports that in 2017, there were 315,000 new BC cases, with
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40,000 deaths. The probability of recurrence is 20%, with 60% to 80% of recurrences
occurring within the first three years [7].
Moreover, there is a disparity in access to care, which remains a barrier to obtaining
adequate BC screening and treatment, particularly in developing nations, but also in
industrialized nations [8-10]. Inadequate health insurance is one of the major barriers to
accessing quality care, even in industrialized nations. Uninsured and underinsured
patients with BC have delayed and limited access to cancer treatment, and interventions
aimed at improving quality of life [11]. The 2016 National Health Interview Survey
(NHIS) showed that there are currently 27.6 million uninsured nonelderly individuals in
the US, with high cost of premiums cited as the primary reason. The report also reflected
poverty as a barrier to being insured, with 80% of uninsured being in families below the
400% Federal Poverty Guidelines level. In addition, the NHIS reported people of color
such as Hispanics (16.9%) and Blacks (11.7%) have higher uninsured rates compared to
Whites (7.6%). These barriers not only hinder BC screening, but they also hinder
adherence to rescreening guidelines [12, 13].
Breast Cancer Treatment and its Impact on Well-Being
The management of BC is becoming increasingly multidisciplinary [14]. This approach
requires the involvement of the primary care physician, geneticist, pathologist, oncologist,
radiologist, surgeons, and radiation oncology specialists [15, 16]. Breast conserving
surgery is the most common treatment for BC, and is accompanied by radiation therapy in
84% of the cases, and chemotherapy in 25% of cases [17]. Treatment can also include
adjuvant endocrine therapy, and neoadjuvant or preoperative systemic chemotherapy [16].
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However, these approaches can exert a significant burden on the physiology and/or
psychology of the BC patient [18], leading to short and/or long term organ system
dysfunction, pain, fatigue, edema, musculoskeletal impairment, and psychosocial
concerns [17]. These effects of therapy can limit the patient’s engagement in activities of
daily living, and become a source of prolonged disability [17].
Health Related Quality of Life
Almost all patients with cancer experience physical and/or psychological symptoms
related to the cancer itself, or the cancer treatment [19]. Cancer is a difficult event with
psychosocial implications, affecting the physical, spiritual, and the emotional well-being
of the patient [20]. The diagnosis of cancer alone (and even benign breast disease) can
cause high levels of anxiety and distress [21], for not only the patient, but also for family
members [22]. Newly diagnosed patients with BC experience negative emotions such as
shock, fear, paralysis, confusion, and despair [23].
Additionally, the psychological impact of BC goes beyond the life threatening nature of
cancer itself, as patients describe distress due to altered body image, sexual dysfunction,
treatment related anxieties, intrusive thoughts with persistent anxiety, marital/partner
communication, vulnerability, fear of recurrence, physical symptoms (such as fatigue,
pain) and existential concerns regarding mortality [24]. Although most women show
good post-treatment psychological adjustment and eventual improvement of Quality of
Life (QoL) [25], certain aspects of QoL have been shown to be affected for up to two
years after primary surgery for breast cancer, such as body image, cognitive functioning,
and insomnia [26]. This is significant given the extended longevity of survivors of BC
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due to improved therapy, which indicates that it is no longer sufficient to simply deal with
the disease, but that improving QoL is also a priority [18].
The psychological response to breast cancer is an important prognostic factor. There is a
significant relationship between psychosocial factors and survival. Depression, denial,
and emotional constraints are linked to a significant decrease in chance of survival, while
social support, marriage, and acceptance are associated with improved prognosis [27, 28].
Ensuring that patients with cancer have good HRQoL is also important because in
situations where treatment options cannot offer cure or disease course modification, they
can still result in significant improvement in the patients’ QoL [29]. Measurements of
HRQoL are reliable and valid, and outcomes have been shown to be responsive to clinical
changes [30], further emphasizing the need to include treatment and or adjuvant options
that improve HRQoL. Negative psychological symptoms are more severe during the
diagnosis and active treatment of BC [24]; and importantly, initial distress around the
time of therapy was found to be the most potent predictive factor for long term HRQoL
[26], thereby highlighting the urgency to initiate such options at the onset of therapy.
Given the important influence of QoL on clinical decision-making, studies have been
increasingly including HRQoL as main end points [31, 32]. HRQoL and QoL are often
incorrectly used interchangeably, but they are not indistinguishable [33]. QoL is
commonly seen as the way an individual subjectively evaluates one’s life through diverse
perspectives such as good physical health, happiness, and life satisfaction [34, 35]. Others
have described that human needs (psychological, physical, social, marital, structural, etc.)
are the basis for QoL, and that the degree of satisfying those needs determine the extent of
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QoL [36]. QoL is broader than HRQoL as it includes non-health related features [37],
whereas HRQoL concerns the aspects of QoL that are relevant to health [38]; that is, it
assesses how the patient’s QoL is affected by an illness and/or the treatment [37]. As
such, HRQoL is a multidimensional representation of patients’ perceptions of the effect
that disease and therapy have on their psychological, physical, and social well-being [39]
(Table 1).
Table 1. Some Definitions of QoL/HRQoL Commonly Seen in the Literature [40]:
QoL

HRQoL

The subjective evaluation of the good and

The functional effect of an illness and its consequent

satisfactory character of life as a whole

therapy upon the patient as perceived by the patient

The gap between the patient’s expectations and

The state of well-being that is a composite of two

achievements. The smaller the gap, the higher the

components: the ability to perform everyday

quality of life

activities that reflect physical, psychological, and
social well-being; and patient satisfaction with
levels of functioning and control of the disease

An individual’s overall satisfaction with life and

The extent to which one’s usual or expected

general sense of personal well-being

physical, emotional and social well-being are
affected by a medical condition or its treatment [41]

The individual’s perception of their position in life

The physical, psychological and social domains of

in the context of the culture and value systems in

health, seen as distinct areas that are influenced by a

which they live and in relation to their goals,

person’s experiences, beliefs, expectations and

expectations, standards, and concerns

perceptions [42]

HRQoL covers the subjective perceptions of both the positive and negative characteristics
of the patient’s symptoms [40]. Assessment and quantification is completed using
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patient-reported questionnaires, as opposed to clinician-reported. There is poor
correlation between clinician assessment of the severity of the patients’ symptoms
compared to the patients’ self-reporting [40]. HRQoL is multidimensional, consisting of
specific domains, each referring to a category of a health related dimension [43]. Each
domain focuses on distinct yet interrelated (and in some cases reciprocal) aspects of the
patient’s health [44].
There is consensus that there are three main domains: the physical, the psychological, and
the social features of health [40], although spirituality is increasingly being considered as
another primary domain [45]. These four domains are known in BC HRQoL literature as
Ferrell’s QoL domains based on the framework completed by Ferrell and colleagues [4548]. Other domains, or subdomains thereof, include – but are not limited to – fatigue, role
activities, emotional well-being, economics, overall life satisfaction, perceptions of health
status [49]; sexuality [50], as well as vitality, pain, and cognitive function [30]. The
number of domains and their categorization varies in the literature and in the instruments
designed to measure them depending on the degree of generality desired [51].
Health Related Quality of Life Domain - Fatigue
Cancer-related fatigue (CRF) is the most common adverse event reported by patients with
cancer [52, 53]. It is defined as feeling of weakness, tiredness, and lack of energy, that is
not relieved by rest or sleep [54]. Acute fatigue experienced after physical or emotional
exertion is normally perceived. In contrast, CRF is disproportionately higher to the level
of exertion, and is more chronic [53]. Up to 90% of patients receiving radiation, and 80%
of those receiving chemotherapy experience fatigue.
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Psychosocial factors contribute to the development of CRF, as it correlates with
depression, anxiety, sleeping disorders, and other psychiatric comorbidities [55].
Additionally, there are somatic factors that contribute to the development of CRF.
Although the exact mechanism is not completely understood, contributory somatic factors
include deficiencies in vitamins and proteins secondary to malnutrition, build-up of toxic
metabolites, infections, overuse of pain and sleep medication, organ dysfunction, and
anemia [53, 55].
Patients with cancer have reported that CRF affects their daily living more than pain, and
it is often overlooked and undertreated [52]. CRF also contributes to the deterioration of
the physical and psychological QoL [53], and limits the patient’s ability to return to work
[54]. CRF increases during active therapy for cancer, and decreases towards the end [55];
however, CRF can persist for months and even years after completion of therapy [54].
This highlights the importance of addressing CRF during active cancer therapy, and to
avoid delays. Likewise, measuring CRF and following its progress throughout therapy is
necessary in order to ensure that CRF is being managed appropriately.
HRQoL and Fatigue Measuring Instruments
HRQoL instruments and the domains they measure depend on their classification as
either generic, general cancer, cancer site-specific, or even cancer problem-specific
instruments [56]. The European Organization of Research and Treatment of Cancer
Quality of Life Questionnaire – Core Questionnaire 30 (EORTC QLQ-C30) is the most
widely used instrument for assessing cancer HRQoL [17], and structures its domains as
follows: 1) Functional domains (subdomains: physical, role, emotional, cognitive, social,
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and global QoL); 2) Symptom domains (subdomains: fatigue, nausea/vomiting, and pain);
and 3) Single-Item domain (subdomains: dyspnea, appetite loss, sleep disturbance,
constipation, and diarrhea) [45]. The EORTC QLQ-C30 is an example of a
multidimensional instrument that measures fatigue in addition to multiple other domains.
Conversely, there are unidimensional instruments that measure only fatigue, such as the
Brief Fatigue Inventory (BFI), and the Functional Assessment of Chronic Illness Therapy
Fatigue (FACIT) module [55]. Most cancer studies measure CRF using multidimensional
instruments [57]. It is possible to aggregate the scores of the domains to obtain a single,
convenient score that would represent overall HRQoL [58]. Domain scores can also be
reported individually, thereby providing more detailed information about how each aspect
is influenced by the disease and treatment [59].
Exercise
There is strong evidence supporting exercise as a non-pharmacological intervention for
CRF [60]. The term Physical Activity (PA) is defined as any activity that results in any
body movement using skeletal muscles leading to an increase in energy expenditure. The
term exercise is often used interchangeably with PA, but is usually defined as a specific
type of PA involving a planned and repetitive body movement aimed at improving
fitness, and measured through the parameters of frequency, intensity, and duration [39,
61]. Energy expending exercise is broadly classified as either aerobic, anaerobic or
strength/resistance training, or a combination of both, and trials typically report and
describe the tools used in the exercise regimen (swimming, cycling, treadmill, weight
training, etc.) [39]. For our purposes, we will be addressing exercise as defined above,
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and exercise type shall refer to whether the regimen was either aerobic, anaerobic
(strength/resistance training), or both (Figure 1).
Figure 1. Parameters of Exercise Regimens.

Exercise and Fatigue
Exercise is a non-pharmacological, effective, safe, and low-cost activity [18] that has
been shown to positively influence overall HRQoL and fatigue [39, 60, 62]. Moreover,
exercise has well documented effects on mental health symptoms highly correlated with
CRF, such as reducing depression, social withdrawal, and anxiety; improving sleep and
interest in sex; increasing endurance; relieving stress; increasing stamina and energy; and
improving cognitive function, mood, and self-esteem [63]. It is thought that exercise
ameliorates fatigue in cancer patients by improving cardiovascular fitness, muscle
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strength, and increasing physical functioning in daily activities [64]. This counteracts the
muscle catabolism and subsequent decrease in functional capacity that occur during
cancer treatment [65].
However, the current literature regarding exercise’s effect on fatigue in BC is limited by
the heterogeneity with regard to the timing of the exercise interventions, as trials
commence the intervention either pre-treatment, during treatment (active), or posttreatment [66]. Moreover, there is consistent underreporting of detailed descriptions of
the exercise regimens used in studies. Without consistency (which is necessary for
reproducibility), an appropriate translation of the findings cannot be made, thereby
limiting the ability to determine the dose of exercise received by the participants [61, 67].
As a result, the type of exercise (aerobic vs. anaerobic vs. combination) and/or its
intensity (mild vs. moderate vs. strenuous/vigorous) having the largest influence on
overall HRQoL or fatigue is yet to be determined [61, 67, 68].
The aims of this systematic review are as follows:
1- Evaluate the effectiveness of exercise interventions on fatigue among women in
active treatment for BC at 12 weeks after the start of the exercise intervention.
2- Compare the different intensities of exercise regimens (mild, moderate, or
vigorous/strenuous) in ameliorating fatigue in women undergoing active therapy
for BC at 12 weeks post-intervention.
3- Determine what exercise type (anaerobic, aerobic, or combination) has the
greatest impact on fatigue in women undergoing active therapy for BC at 12
weeks post-intervention.
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Methods
Studies Selection
The authors included trials that met the following inclusion criteria: (1) Randomized
Controlled Trials (RCTs), or controlled clinical trials (CCTs); (2) Breast cancer as the
primary cancer; (3) Adult participants (≥18 years of age); (4) Compared an exercise
intervention to a non-exercise control; (5) Exercise intervention was started during active
cancer therapy; and (6) Fatigue measured as an outcome. We excluded trials if: (1)
Participants were terminally ill; (2) Participants were receiving hospice care; (3) Exercise
intervention was started after completion of cancer therapy; or if (4) Exercise intervention
was completed before start of cancer therapy.
Exercise was defined as any regimen that lead to an increase in energy expenditure, and
followed a planned and repetitive body movement with a specified frequency, intensity,
and duration [39, 61]. Exercise intensity was classified as mild, moderate, or vigorous;
and exercise type was classified as either aerobic, anaerobic, or both.
The primary outcome was change in CRF, whether it was obtained from a unidimensional
instrument, or from a multidimensional instrument. Change in CRF was evaluated as the
value at 12 weeks after the start of the exercise intervention compared to prior to the start
of the intervention.
Literature Search
This systematic review is part of a project to update a Cochrane Registered Systematic
Review by Mishra et al. [39] which examines exercise’s effect on HRQoL in patients
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with all types of cancers that are undergoing active treatment. We systematically searched
the following databases: PubMed, Cochrane Central Register of Controlled Trials
(CENTRAL), Medline, EMBASE, CINAHL, SportDisc, PsycINFO, PEDro, LILACS,
SIGLE, and OTSeeker. Additionally, we searched citations using Web of Science and
Scopus, and PubMed’s related article feature. We also examined the reference list of the
articles that fit our eligibility criteria.
Articles published up until the 31st of December 2016 were selected, with no restriction
on language or date. An initial search strategy was conducted for Medline, and was
adjusted for the other databases. Screening for eligibility was based on titles and
abstracts, after which the full-text was examined to confirm eligibility. Two independent
reviewers completed the screening, and disagreements were resolved by consensus or by
adjudication through a third reviewer.
Data Collection
The data of the selected articles were screened, and when applicable, extracted by two
independent reviewers using standardized forms, and verified through consensus. A third
reviewer arbitrated when necessary. Data collected from each article included study
characteristics, eligibility criteria, number of participants randomized into each arm,
description of the control group, demographics, cancer treatment regimen, cancer type
and stage, age at diagnosis, and time since diagnosis. Description of the exercise
intervention was also extracted, including type, intensity, frequency, duration, number of
sessions, exercise format, location, participants, and professionals involved. Adherence,
compliance, and contamination rates were also extracted, as well as fatigue outcome
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measures, time at which the measurement was made, and side effects. For missing or
unclear information/data in a study, we attempted to contact the primary author. Every
trial was graded for risk of bias (low, high, or unclear).
The time point for the fatigue outcome was 12 weeks after the start of the exercise
intervention. If the 12-week time-point was not reported, we then selected the time point
closest to the 12 weeks follow-up up to 4 weeks before or after the 12 week mark. The
unit of analysis was the BC patient undergoing active BC therapy randomized to either
the exercise intervention group or control group.
The intensity of the activity can be quantified subjectively by assessing rate of perceived
exertion of the patient via an interview or self-completed questionnaire; or objectively
such as by changes in heart rate and/or recordings of an accelerometer – the most widely
used objective measure of exercise [69]. When such measurements are not available,
exercise intensity is classified as mild, moderate, or vigorous/strenuous [39]. Mild or light
intensity exercise refers to daily activities such as shopping, and working around the
house. Moderate intensity exercises expend effort equivalent to a brisk walk, whereas
strenuous intensity exercises engage the large muscle groups and cause an evident
increase in heart rate [70].
Data Analysis
Data was collected and entered into the software Review Manager – Version 5 (RevMan
5), which was developed and is maintained by Cochrane Reviews for systematic reviews
and meta-analyses. A meta-analysis was performed on the change in scores from baseline
to the 12 week follow-up. Trials were pooled for random effects meta-analysis for the
13

intervention effect estimate (odds ratio and a 95% confidence interval). A weighted mean
difference was used for trials using the same instrument for reporting fatigue outcome,
and a standardized mean difference was used when the instruments between the trials
were different, in which case differences were reported as units of standard deviation
[39].

Results
Study Characteristics
Following the systematic literature search, 186 potential non-duplicate articles were
retrieved, 76 of which met the eligibility criteria. Of the 76 records meeting the inclusion
criteria, 5 were ongoing studies, and an additional 28 were secondary publications, and
therefore not included. A total of 43 articles remain on which qualitative synthesis was
performed (Figure 2).
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Figure 2. Study Selection PRISMA Flow Diagram.

Non-duplicate studies identified by
database searching (n=186)
Studies excluded for not meeting
eligibility criteria (n=110)
Full-text articles assessed (n=76)

Ongoing studies excluded (n=5)

Secondary publications excluded
(n=28)

Full-text articles included in
qualitative synthesis (n=43)

Full-text articles included in
quantitative synthesis (n=18)

Of the 43 trials included, 42 were RCTs, and only one was a CCT. Four studies
randomized the participants to more than two study arms, the additional arm consisting of
an additional variation in the exercise regimen. The remaining 39 studies had two arms:
exercise and non-exercise (control) arms.
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Participants
A total of 4826 participants were randomized, 2286 of which were randomized to the
exercise intervention, and 1985 to the control group. The mean age of participants ranged
between 28 and 75 years, with four studies reporting age as a median instead of a mean.
Ethnicity was reported in 17 trials, education in 27, employment in 20, previous exercise
history in 15 studies, and socio-demographic status in 11. Fourteen trials reported BMI,
and mean BMI ranged from 23kg/m2 to 29kg/m2 in the intervention group, and 24kg/m2
to 30kg/m2in the control group. The treatment regimen was chemotherapy in 17 trials,
and radiotherapy in 8 trials.
Exercise Interventions
The exercise regimens varied across studies. Twenty-two trials consisted of an aerobic
intervention, two trials consisted of an anaerobic/resistance training regimen, and 19 trials
had a combined aerobic and anaerobic intervention. Two studies had two exercise
intervention arms, each comprising of either an aerobic or an anaerobic intervention. The
duration of the exercise program ranged from 5 weeks to 8 months (modal program
duration = 12 weeks in 17 trials). The frequency of the exercise sessions ranged from one
time a week to daily (modal frequency = three times a week in 17 trials). Duration of the
individual exercise sessions ranged from 10 minutes to 90 minutes (modal session
duration = 60 minutes in nine trials).
Exercise intensity was measured by subjective reporting of the participants in two trials,
both using the Borg Exertion Scale. Fifteen studies measured intensity objectively: as a
percent of maximal heart rate (n=10), maximal oxygen consumption (n=3), and as a
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percent of one maximal repetition/power output for resistance/anaerobic training (the
maximum resistance of which a person can complete at least one repetition) (n=6). Two
trials used multiple objective measurements, and two trials measured intensity both
objectively and subjectively. Nine studies had a planned increase in the intensity of the
exercise once certain milestones were met.
The intensity was categorized in 20 studies; as mild (n=8), moderate (n=5), mild to
moderate (n=2), moderate to strenuous (n=4). One study reported that the intensity varied
from mild to rigorous depending on the participant, one other reported a scheduled
progression in increasing intensity from mild to vigorous, and one study reported intensity
as “varied” with no other specifics. Only four studies recorded objective measurements to
accompany the category of the description. On the other hand, 14 studies reported
objective measurements of the exercise intensity, but did not describe the exercise
regimen in the mild/moderate/strenuous categories. In these cases, we used the American
College of Sports Medicine’s (ACSM) classification system, which categorizes the
exercise intensity as mild/moderate/strenuous based on the objective measurements (such
as percent of maximal heart rate and rate of exertion). Nine studies did not report exercise
intensity either objectively nor subjectively.
Outcomes
Seventeen studies measured fatigue scores using 8 multidimensional instruments, the
most common ones were the EORTC QLQ-C30 (n=4) and the Medical Outcomes 36Item Short Form Health Survey (MOS SF-36) (n=4). Thirty-three trials measured fatigue
using unidimensional instruments solely for fatigue (one of which measuring attentional
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fatigue), the most common ones were the Piper Fatigue Scale (n=8), the Functional
Assessment of Chronic Illness Therapy – FACT-F (n=7), and the Brief Fatigue Inventory
(n=7). Fatigue at 12 weeks significantly decreased in the exercise group compared to the
control group (Standard Mean Difference (SMD) = -0.11; 95% CI: -0.22 to -0.01) (Figure
3).
Figure 3. Effect of Exercise on Fatigue.

When analyzed according to exercise regimen intensity, regimens categorized as mild did
not have a significant effect on fatigue scores at 12 weeks compared to controls (SMD =
0.21; 95% CI: 0.02 to 0.39) (Figure 4). The moderate intensity studies showed no
significant difference when compared to controls (SMD = -0.03; 95% CI: -0.22 to 0.15).
Of the four studies categorized as strenuous, two had eligible data, and the analysis
showed no significant difference between the exercise intervention and the control group
(SMD = 0.18; 95% CI: -0.34 to 0.69). Due to the low number of strenuous regimen
18

studies, we combined them with the moderate intensity studies. Our analysis showed that
this group’s results favor the exercise intervention in improving fatigue outcomes over
the control group, although it was not statistically significant (SMD = -0.10; 95% CI: 0.25 to 0.06) (Figure 5).
Figure 4. Effect of Mild Intensity Exercise on Fatigue Outcomes.

Figure 5. Effect of Moderate and Strenuous Intensity Exercise on Fatigue Outcomes.

According to exercise type, the aerobic intervention showed a significant improvement in
fatigue scores at 12 weeks compared to baseline (SMD = -0.19; 95% CI: -0.37 to -0.01)
(Figure 6). Of the four studies with exercise regimens consisting of anaerobic regimens
only, one of them had eligible data, and showed non-significant effect on fatigue scores
(SMD = -0.14; 95% CI: -0.54 to 0.25). The combination regimens equally showed no
19

effect on fatigue scores compared to controls (SMD = 0.04; 95% CI: -0.14 to 0.21)
(Figure 7).
Figure 6. Effect of Aerobic Exercise on Fatigue.

Figure 7. Effect of Combination Exercise on Fatigue.

Risk of Bias
The risk of bias was moderate to high in all studies selected. Performance bias was high
in all trials as a result of the knowledge of the intervention by the participants. Selection
bias was low in most studies due to use of appropriate randomization sequences, whereas
detection and attrition biases were high (Figure 8).
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Figure 8. Risk of Bias

Discussion
Our study showed that exercise during BC therapy significantly improves fatigue
outcomes in patients with BC at 12 weeks. Our analysis also showed that no exercise
intensity is superior to another. We also showed that aerobic regimens significantly
improved fatigue outcomes in patients with BC at 12 weeks, but that neither anaerobic
nor combination regimens showed such statistical effect.
Upon reviewing the literature, we found that most research includes exercise regimens
initiated after therapy completion. A systematic review by Fairman et al. in 2016
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examined exercise regimens only during active BC therapy in 17 studies [71]. Their
results were reported based on the cancer therapy received: chemotherapy (CX), radiation
(RT), chemotherapy and radiation (CXRT). They found that fatigue improved in patients
on CX receiving resistance training (although the effect was negligible), and that fatigue
worsened for those on combination exercise regimens, but that included only one trial.
For patients receiving CXRT, large improvement in fatigue was seen in both aerobic, and
anaerobic exercise regimens, but there were no studies with combination exercise
regimens. The possible explanations for the differences with our results could be
attributed to study selection (different inclusion criteria), their use of different time points
at which outcomes were measured, and their use of Cohen’s d effect size for calculating
the results.
Our results are in agreement with the literature that exercise generally improves HRQoL
and fatigue outcomes among patients who have completed cancer therapy [39, 72, 73].
However, another review found that the effect of aerobic exercise was non-significant,
but that combination and anaerobic-only regimens had a significant effect on fatigue [73].
A review by Zeng et al. found that exercise significantly improves QoL in patients with
cancer, and sub-group analysis revealed that aerobic exercise showed significant results,
but that combination regimens did not (anaerobic-only analysis was not done) [72].
A potential explanation for the differences in findings is the high level of heterogeneity
among studies. Studies vary by eligibility criteria, timing of treatment, exercise regimens,
and instruments used for measuring outcomes. Inter-study variability is a potential barrier
to accurate estimation of the differences in exercise regimens. Furthermore, bias was
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moderate to high in all studies. Masking of participants and personnel was evidently high
as it is not possible to blind either to the intervention. Reporting, detection, and attrition
biases were also high. On the other hand, most studies had low selection bias as random
sequences were most often adequately generated.
In our review, there was significant heterogeneity in the intensity of the exercise
regimens, in the reporting of the intensity, and in the categorization of the intensity. Of
the 20 studies that reported intensity as a category, only four complemented the intensity
description with objective measurements. Nine studies did not report intensity either by
objective measurement or by categorization. We were able to use the ACSM
classification system for aerobic type exercise by converting objective measurements
(such as percent of maximal HR) to intensity category, but such conversion system is not
available for anaerobic exercise regimens.
Variability was also evident in outcome reporting. Fifteen instruments were used to report
outcomes, 8 of which were multidimensional instruments, and 7 were unidimensional and
unique for fatigue. Although we used the data from the more commonly used instruments,
and used SMD analysis in order to compile the results together, this did not account for
clinically significant effects detectable within each instrument. The multitude of
measuring instruments prompted us to recommend psychometric analysis for the
construct validity of the scales used, and between the different scales. This allowed better
comparisons across the different scales used, and better interpretation of the results and
their implication in clinical practice. This issue may be resolved with the consistent and
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uniform use of the Patient Reported Outcomes Measurement Information System
(PROMIS) [74].
In order for future studies to provide clearer understanding of what exercise regimens are
effective in improving fatigue (and other HRQoL outcomes), the description of the
exercise regimens needs to be more detailed. Ideally, all studies should report exercise
intensity by objective measures that can be reproduced in other trials, and that can be
compared to other studies without the need for conversion systems. This will allow the
determination of what exercise regimens are effective in clinical practice.
Surprisingly, the reporting of the demographic information of the study participants was
poor across studies. Only 40% of studies reported ethnicity, 26% socio-economic status,
and 33% BMI. The poor reporting of demographics across studies limits generalizability
and can also potentially account for the results obtained. Previous exercise history was
reported only in 35% of the trials, and this parameter also needs to be reported better in
order to account for potential contamination, and to better understand the effect of an
exercise history on treatment effects on cancer. Future studies should collect and present
these parameters more consistently.
Most studies compared an exercise regimen to a non-exercise control. Only two studies
had two exercise regimens in addition to the control. This indicates that there is a need to
conduct studies comparing different exercise regimens to each other (such as comparing
an aerobic regimen to an anaerobic regimen), in order to better estimate which ones are
more effective, and consequently help guide in the clinical management of patients with
BC.
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For cancer prevention, the American Cancer Society (ACS) recommends a minimum of
150 minutes of moderate-to-strenuous exercise a week; to consume a minimum of 5
servings of vegetables and fruits a day; and to not smoke [75]. Studies have shown that
cancer patients who adhere to the exercise portion set by the ACS had better HRQoL
outcomes than those who did not [62, 76]. Although all three lifestyle modifications
recommendations of the ACS improved HRQoL independently, exercise showed the
strongest association [77].
The ACS recommends exercise during cancer therapy, and maintaining activity as much
as possible [75]. The ACSM concluded that exercise is safe and efficacious in improving
fatigue during cancer treatment. It suggests that the exercise regimen should be
individualized according to the cancer type, the individual preferences, and to the therapy,
[78]. This highlights the importance of implementing an exercise regimen during cancer
therapy.
While there are specific recommendations for exercise regimens for the prevention of
cancer, and for cancer survivors, there are no specific recommendations for regimens
during active therapy. Although individualized regimens are recommended, there are
currently no standardized guidelines that can help guide either the patient or the clinicians
in prescribing an individualized exercise regimen in active treatment. Moreover, there is a
lack

of

awareness

by

healthcare

providers

regarding

appropriate

exercise

recommendations [79]. Given the benefits of exercise regimens, and the importance of
starting as early as early as possible, we agree with the literature that more research is
needed to determine the optimal exercise parameters in the categories of intensity,
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regimen duration, type, frequency, and session duration [39, 72]. This will allow specific
instructions to be provided, and for the patients and clinicians to have a reference during
active cancer therapy.

Conclusion
Our review demonstrated that exercise, specifically aerobic type, is effective in improving
fatigue outcomes at 12 weeks in patients with BC undergoing active therapy. However,
the heterogeneity of regimens and in outcomes reporting in the literature are substantial.
This is a potential reason that can explain why other regimens were not found to be
effective. We also found that there is a lack of guidelines for exercise regimens during
active cancer treatment. The variability in exercise regimens allows for many choices to
select from, but it is not known which ones are clinically effective. This highlights the
necessity to conduct more robust studies that can help in establishing specific regimens
and recommendations to guide the patients and the clinicians. Exercise is a safe and
efficacious intervention that can provide significant short and long-term benefits to
fatigue and HRQoL to patients with BC. Establishing guidelines is urgently needed, and
can be an important step in improving outcomes.
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